Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: Results of a phase I-II study

Blood

Volumn 98, Issue 3, 2001, Pages 565-572

  Bunjes, Donald ^a   Buchmann, Inga ^a   Duncker, Christian ^a   Seitz, Ulrike ^a   Kotzerke, Jörg ^a   Wiesneth, Markus ^a   Dohr, Dagmar ^a   Stefanic, Martin ^a   Bück, Andreas ^a   Harsdorf, Stefanie V ^a   Glatting, Gerhard ^a   Grimminger, Wolfgang ^a   Karakas, Tunca ^a   Munzert, Gerd ^a   Döhner, Hartmut ^a   Bergmann, Lothar ^a   Reske, Sven N ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTIGRANULOCYTE; BUSULFAN; CYCLOPHOSPHAMIDE; HLA ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD66A; MONOCLONAL ANTIBODY CD66B; MONOCLONAL ANTIBODY CD66C; MONOCLONAL ANTIBODY CD66E; RHENIUM; THIOTEPA; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGRAFT; ANEMIA; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSIMETRY; FEMALE; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY DISEASE; LEUKEMIA REMISSION; LIVER TOXICITY; MALE; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RELAPSE; STEM CELL TRANSPLANTATION; STOMATITIS; T LYMPHOCYTE; VEIN OCCLUSION; WHOLE BODY RADIATION;

EID: 0035437130     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.3.565     Document Type: Article

References (68)

1. Mayer R, Davis R, Schiffer C, et al. Intensive post-remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994;331:896-903.
2. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-2333.
3. Wheatley K, Burnett A, Goldstone A, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. Br J Haematol. 1999;107:69-79.
4. Mrozek K, Heinonen K, de la Chapelle A, Bloomfield CD. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol. 1997;24:17-31.
5. Greenberg P, Cox C, LeBeau M, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
6. Thomas E, Buckner C, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic bone marrow transplantation. Blood. 1977;49:511-533.
7. Biggs J, Horowitz M, Gale R, et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission. Blood. 1992;80:1090-1093.
8. Clift R, Buckner C, Thomas E, et al. The treatment of acute nonlymphocytic leukemia by allogeneic bone marrow transplantation. Bone Marrow Transplant. 1987;2:243-258.
9. Anderson J, Appelbaum F, Fisher L, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood. 1993;82:677-681.
10. Horowitz M. Results of allogeneic stem cell transplantation for malignant disorders. In: Hoffman R, Benz E, Shattil S, Furie B, Cohen H, Silberstein L, McGlave P, eds. Hematology, Basic Priciples and Practice. Vol 1. 3rd ed. Philadelphia, PA: Churchill Livingstone; 1999:1573-1587.
11. Gale R, Horowitz M, Weiner R, et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant. 1995;16:203-208.
12. Ferrant A, Labopin M, Frassoni F, et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Blood. 1997;90:2931-2938.
13. Appelbaum F. Allogeneic hematopoietic stem cell transplantation for acute leukemia. Semin Oncol. 1997;24:114-123.
14. Auer I, Gale R. Are new conditioning regimens for transplantation in acute myelogenous leukemia better? Bone Marrow Transplant. 1991;4:255-262.
15. Clift R, Buckner C, Appelbaum F, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood. 1990;76:1867-1871.
16. Clift R, Buckner C, Appelbaum F, et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase. A randomized trial of two irradiation regimens. Blood. 1991;77:1660-1665.
17. Papadopoulos E, Carabasi M, Castro-Malespina H, et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood. 1998;91:1083-1090.
18. Marmont A, Horowitz M, Gale R, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood. 1991;78:2120-2130.
19. Horowitz M, Gale R, Sondel P, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-562.
20. Matthews D, Appelbaum F, Eary J, et al. Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque. Blood. 1991;78:1864-1874.
21. Appelbaum F, Matthews D, Eary J, et al. The use of radiolabelled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation. 1992;54:629-633.
22. Matthews D, Appelbaum F, Eary J, et al. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131-1 labelled anti-CD45 antibody combined with cyclophosphamide and total body irradiation. Blood. 1996;85:1122-1131.
23. Jurcic J, Caron P, Nikula T, et al. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res. 1995;55(suppl 23):5908a-5910a.
24. Matthews D, Appelbaum F, Eary J, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood. 1999;94:1237-1247.
25. Reske SN, Karstens JH, Gloeckner W, et al. Radioimmunoimaging for diagnosis of bone marrow involvement in breast cancer and malignant lymphoma. Lancet. 1989;1(8633):299-301.
26. Reske S. Recent advances in bone marrow scanning. Eur J Nucl Med. 1991;18:203-221.
27. Becker W, Goldenberg D, Wolf F. The use of monoclonal antibodies and antibody fragments in the imaging of infectious lesions. Semin Nucl Med. 1994;25:1-13.
28. Noworolska A, Hardoszinska A, Richter R, Brodzka W. Non-specific cross-reacting antigen (NCA) in the individual maturation stages of myeloid cell series. Br J Cancer. 1985;51:371-377.
29. Noworolska A, Hardozinska A, Buchegger F, Lawinska B, Richter R. Expression of non-specific cross-reacting antigen species in myeloid leukemic patients and healthy subjects. Blut. 1989;58:69-73.
30. Bordessoule D, Jones M, Gatter K, Mason D. Immunohistological patterns of myeloid antigens: tissue distribution of CD13, CD14, CD16, CD31, CD36, CD65, CD66 and CD67. Br J Haematol. 1993;83:370-383.
31. Boccuni P, Di Noto R, Lo Pardo C, et al. CD66c antigen expression is myeloid restricted in normal bone marrow but is a common feature of of CD10+ early B-cell malignancies. Tissue Antigens. 1998;52:1-8.
32. Carrasco M, Munoz L, Bellido M, etal. CD66 expression in acute leukaemia. Ann Haematol. 2000;79:299-303.
33. Schubinger P, Hasler P, Novak-Hofer I, Bläuenstein P. Assessment of the binding properties of Granuloszint. Eur J Nucl Med. 1989;15:605-608.
34. Press O, Appelbaum F, Eary J, Bernstein I. Radiolabeled antibody therapy of lymphomas. In: De Vita VT, Hellmann S, Rosenberg S, eds. Important Advances in Oncology 1995. Philadelphia, PA: Lippincott; 1995:157-171.
35. Knapp F, Mirzadeh S. The continuing important role of radionuclide generator systems for nuclear medicine. EurJ Nucl Med. 1994;20:1151-1165.
36. Seitz U, Neumaier B, Glatting G, Kotzerke J, Bunjes D, Reske S. Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia. Eur J Nucl Med. 1999;26:1265-1273.
37. Kotzerke J, Glatting G, Seitz U, et al. Radioimmunotherapy for the intensification of conditioning prior to stem cell transplantation: differences in dosimetry and biokinetics of Re-188 and Tc-99mlabeled monoclonal anti NCA-95 antibodies. J Nucl Med. 2000;41:531-537.
38. Stabin M. MIRDOSE: the personal computer software for use in internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-546.
39. Luxton R, Kunkler P. Radiation nephritis. Acta Radiol Ther Phys Biol. 1964;2:169-178.
40. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-122.
41. Hale G, Jacobs P, Wood L, et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant. 2000;26:69-76.
42. Handgretinger R, Schumm M, Lang P, et al. Transplantation of megadoses of purified haploidentical stem cells. Ann N Y Acad Sci. 1999;872:351-360.
43. Jacobs P, Wood L, Fullard L, Waldmann H, Hale G. T-cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease. Bone Marrow Transplant. 1994;13:763-769.
44. Hertenstein B, Hampl W, Bunjes D, et al. In vivo/ex-vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant. 1995;15:387-397.
45. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295-304.
46. Bearman S, Appelbaum F, Buckner C. Regimenrelated toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6:1562-1568.
47. Cohen E, Lawton C, Moulder J. Bone marrow transplant nephropathy: radiation nephritis revisited. Nephron. 1995;70:217-222.
48. Schwartz M, Lovett D, Redner A, et al. Dose-escalation trial of M 195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol. 1993;11:294-303.
49. Nourigat C, Badger C, Bernstein I. Treatment of lymphoma with radiolabeled antibody: elimination of tumor cells lacking target antigen. J Natl Cancer Inst. 1990;82:47-50.
50. Reske S, Bunjes D, Buchmann I, et al. Tumor cell kill by friendly fire: radioimmunotherapy with a bone marrow selective rhenium-188 CD66a, b, c, e antibody in the conditioning of high risk leukaemia patients prior to stem cell transplantation. Eur J Nucl Med. In press.
51. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689-694.
52. Plaizier M, Roos J, Teule G, et al. Comparison of non-invasive approaches to red marrow dosimetry for radiolabelled monoclonal antibodies. Eur J Nucl Med. 1994;21:216-222.
53. Sgouros G, Jureidini I, Scott A, Graham M, Larson S, Scheinberg D. Bone marrow dosimetry: regional variability of marrow-localizing antibody. J Nucl Med. 1996;37:695-698.
54. Buchsbaum D, Roberson P. Experimental radioimmunotherapy: biological effectiveness and comparison with external beam radiation. In: Sautter-Bihl M-L, Bihl H, Wannenmacher M, eds. Systemic Radiotherapy with Monoclonal Antibodies. Berlin: Springer; 1996:9-18.
55. Behr T, Sharkey R, Sgouros G, et al. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates. Cancer. 1997;80(suppl):2591-2610.
56. Rowlings P, Sobocinsky K, Zhang M-J, Klein J, Horowitz M. Multicentre observational databases in bone marrow transplantation. In: Barrett J, Treleaven J, eds. The Clinical Practice of Stem-Cell Transplantation. Vol 2. Oxford: Isis; 1998:896-911.
57. Zager R. Acute renal failure in the setting of bone marrow transplantation. Kidney Int. 1994;46:1443-1458.
58. Lawton C, Cohen E, Barber-Derus S, et al. Late renal dysfunction in adult survivors of bone marrow transplantation. Cancer. 1991;67:2795-2800.
59. Miralbell R, Bieri S, Mermillod B, etal. Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total body irradiation and graft-versus-host disease. J Clin Oncol. 1996;14:579-585.
60. Rabinowe S, Soiffer R, Tarbell N, et al. Hemolyticuremic syndome following bone marrow transplantation in adults for hematologic malignancies. Blood. 1991;77:1837-1844.
61. Guinan E, Tarbell N, Niemeyer C, Sallan S, Weinstein H. Intravascular hemolysis and renal insufficiency after bone marrow transplantation. Blood. 1988;72:451-455.
62. Paller M. Bone marrow transplantation nephropathy. J Lab Clin Med. 1994;124:315-317.
63. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassaemia. N Engl J Med. 1990;336:850-854.
64. Lawton C, Cohen E, Murray K, et al. Long-term results of selective renal shielding in patients undergoing total body irradiation in preparation for bone marrow transplantation. Bone Marrow Transplant. 1997;20:1069-1074.
65. Hansen J, Gooley T, Martin P, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962-968.
66. Szydlo R, Goldman J, Klein J, et al. Results of bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997;15:1767-1777.
67. Hale G, Zhang M-J, Bunjes D, et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood. 1998;92:4581-4590.
68. Bunjes D, Hertenstein B, Wiesneth M, et al. In vivo/ex vivo T cell depletion reduces the morbidity of allogeneic transplantation in patients with acute leukaemias in first remission without increasing the risk of treatment failure: comparison with cyclosporin/methotrexate. Bone Marrow Transplant. 1995;15:563-568.